Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

BACKGROUND: In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer (SCLC). METHODS: EGFR, p-AKT, p-ERK, p-mTOR and p-p70s6K protein express...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schmid, K, Bago-Horvath, Z, Berger, W, Haitel, A, Cejka, D, Werzowa, J, Filipits, M, Herberger, B, Hayden, H, Sieghart, W
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2010
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938245/
https://ncbi.nlm.nih.gov/pubmed/20683448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605761
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak